Ampicillin sodium Injection Rx
Generic Name and Formulations:
Ampicillin sodium 125mg, 250mg, 500mg, 1g, 2g, 10g; per vial; pwd for IV or IM inj after reconstitution and dilution.
Various generic manufacturers
Indications for Ampicillin sodium Injection:
Adults and Children:
Give IV inj slowly over at least 10–15 minutes; rapid IV administration may result in convulsive seizures. Respiratory tract and soft tissue infections: <40kg: 25–50mg/kg per day in equally divided doses every 6–8 hours. ≥40kg: 250–500mg every 6 hours. GI or GU tract infections (including N. gonorrhoeae in women): <40kg: 50mg/kg per day in equally divided doses every 6–8 hours. ≥40kg: 500mg every 6 hours. Urethritis in males due to N. gonorrhoeae: two doses of 500mg each at interval of 8–12 hours. Meningitis: Initiate with IV drip, then continue IM. 150–200mg/kg per day in equally divided doses every 3–4 hours. Septicimia: Initiate IV for at least 3 days, then continue IM every 3–4 hours. 150–200mg/kg per day; treat for at least 10 days if caused by Group A β-hemolytic streptococci.
Cephalosporin, imipenem, other allergy or mononucleosis: not recommended. Monitor blood, renal, and liver function in long-term use. Pregnancy (Cat.B). Nursing mothers.
May cause false (+) glucose test with Clinitest, Benedict's or Fehling's soln. Potentiated by probenecid. May increase risk of rash with allopurinol.
Anaphylaxis, urticaria, GI upset, blood dyscrasias.
Formerly known under the brand names Principen, Totacillin, Pfizerpen-A, Penbritin, Omnipen, Amcill (caps, susp); Polycillin-N, Totacillin-N, Penbritin-S, Omnipen-N (inj).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes In on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma